Thrombolytic therapy for pulmonary embolism

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Thrombolytic therapy is typically reserved for severe pulmonary embolism (PE).
• Evidence suggests thrombolytics may dissolve clots faster than heparin, potentially reducing PE-related mortality.
• Concerns exist regarding increased risks of major or minor hemorrhages with thrombolytic use.

Purpose of the Study:

• To assess the efficacy and safety of thrombolytic therapy in patients diagnosed with acute pulmonary embolism.
• To compare thrombolytic therapy plus heparin versus heparin alone or placebo.

Main Methods:

• Systematic review and meta-analysis of 18 randomized controlled trials (RCTs) involving 2197 participants.
• Included trials compared thrombolytic therapy followed by heparin against heparin alone, heparin plus placebo, or surgery.
• Excluded trials comparing different thrombolytic agents or dosages.

Main Results:

• Thrombolytics plus heparin significantly reduced the odds of death (OR 0.57) and PE recurrence (OR 0.51) compared to heparin alone (low-quality evidence).
• Higher incidence of major (OR 2.90) and minor (OR 3.09) hemorrhagic events observed in the thrombolytic group.
• Stroke risk was elevated in the thrombolytic group (OR 12.10), though with wide confidence intervals.

Conclusions:

• Low-quality evidence suggests thrombolytics reduce mortality in acute PE but increase bleeding complications and stroke risk.
• Thrombolytic therapy may help reduce PE recurrence.
• Further high-quality, double-blind RCTs are necessary to evaluate safety and cost-effectiveness.